

RECEIVED
CENTRAL FAX CENTER
AUG 29 2006

CLAIM AMENDMENTS

1. (currently amended) A recombinant vesicular stomatitis virus (VSV) particle comprising a nucleic acid molecule encoding a foreign glycoprotein inserted into the viral genome wherein the foreign glycoprotein has replaced the native VSV glycoprotein.
2. (currently amended) The recombinant VSV particle according to claim 1 wherein the foreign glycoprotein is a viral hemorrhagic fever (VHF) glycoprotein or an immunogenic fragment thereof.
3. (original) The recombinant VSV particle according to claim 2 wherein the VHF glycoprotein is selected from the group consisting of: a glycoprotein from Lassa virus; a glycoprotein from Marburg virus; a glycoprotein from Ebola virus; a glycoprotein from Crimean-Congo HFV; a glycoprotein from Dengue virus; a glycoprotein from Nipah virus; a glycoprotein from Hendra virus; a glycoprotein from Machupo virus; a glycoprotein from Junin virus; a glycoprotein from Guanarito virus; and a glycoprotein from Sabia virus.
4. Cancelled.
5. (currently amended) The recombinant VSV particle according to claim 1 wherein the nucleic acid molecule is inserted adjacent to the nucleoprotein gene of the viral genome first gene of the recombinant VSV codes for the foreign glycoprotein.
6. cancelled.
7. cancelled
8. cancelled
9. cancelled
10. cancelled
11. cancelled
12. cancelled
13. (currently amended) A method of eliciting an immune response in an individual comprising:
administering to an individual a recombinant vesicular stomatitis virus (VSV)

particle comprising a nucleic acid molecule encoding a foreign glycoprotein inserted into the viral genome wherein the foreign glycoprotein has replaced the native glycoprotein.

14. (currently amended) The method according to claim 13 wherein the foreign glycoprotein is a viral hemorrhagic fever (VHF) glycoprotein or an immunogenic fragment thereof.

15. (original) The method according to claim 14 wherein the VHF glycoprotein is selected from the group consisting of: a glycoprotein from Lassa virus; a glycoprotein from Marburg virus; a glycoprotein from Ebola virus; a glycoprotein from Crimean-Congo HFV; a glycoprotein from Dengue virus; a glycoprotein from Nipah virus; a glycoprotein from Hendra virus; a glycoprotein from Machupo virus; a glycoprotein from Junin virus; a glycoprotein from Guanarito virus; and a glycoprotein from Sabia virus

16. cancelled

17. (currently amended) The method according to claim 13 wherein the nucleic acid molecule is inserted adjacent to the nucleoprotein gene of the viral genome first gene of the recombinant VSV codes for the foreign glycoprotein.

18. cancelled

19. The method according to claim 13 wherein the particle is administered orally.

20. (original) The method according to claim 13 wherein the particle is administered intranasally.

21. (currently amended) A method of preparing a pharmaceutical composition for passive immunization of an individual in need of immunization comprising:

administering to an animal a recombinant vesicular stomatitis virus (VSV) particle comprising a nucleic acid molecule encoding a foreign glycoprotein inserted into the viral genome wherein the foreign glycoprotein has replaced the native VSV glycoprotein;

harvesting antibodies from said animal; and

mixing said antibodies with a suitable excipient or carrier, thereby forming a pharmaceutical composition.

22. (currently amended) The method according to claim 21 wherein the foreign glycoprotein is a viral hemorrhagic fever (VHF) glycoprotein or an immunogenic fragment thereof.

23. (original) The method according to claim 22 wherein the VHF glycoprotein is selected from the group consisting of: a glycoprotein from Lassa virus; a glycoprotein from Marburg virus; a glycoprotein from Ebola virus; a glycoprotein from Crimean-Congo HFV; a glycoprotein from Dengue virus; a glycoprotein from Nipah virus; a glycoprotein from Hendra virus; a glycoprotein from Machupo virus; a glycoprotein from Junin virus; a glycoprotein from Guanarito virus; and a glycoprotein from Sabia virus.

24. cancelled

25. (currently amended) The method according to claim 21 wherein the ~~nucleic acid molecule is inserted adjacent to the nucleoprotein gene of the viral genome~~ first gene of the recombinant VSV codes for the foreign glycoprotein.

26. cancelled

27. (original) The method according to claim 21 wherein the particle is administered orally.

28. (original) The method according to claim 21 wherein the particle is administered intranasally.